Prelude Therapeutics/PRLD

$5.62

7.66%
-
1D1W1MYTD1YMAX

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.

Ticker

PRLD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Krishna Vaddi

Employees

128

Headquarters

Wilmington, United States

PRLD Metrics

BasicAdvanced
$286.69M
Market cap
-
P/E ratio
-$2.05
EPS
1.47
Beta
-
Dividend rate
$286.69M
1.46655
$8.57
$1.66
68K
10.792
-48.91%
-56.33%
-53.6%
1.209
1.209
15.9%

What the Analysts think about PRLD

Analyst Ratings

Majority rating from 4 analysts.
Hold

Price Targets

Average projection from 5 analysts.
3.2% upside
High $10.00
Low $3.00
$5.62
Current price
$5.80
Average price target

PRLD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-33M
7.84%
Profit margin
0%
-

PRLD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.12%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.58
-$0.54
-$0.45
-$0.46
-
Expected
-$0.69
-$0.63
-$0.58
-$0.49
-$0.49
Surprise
-15.33%
-14.74%
-22.72%
-6.12%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Prelude Therapeutics stock?

Prelude Therapeutics (PRLD) has a market cap of $286.69M as of April 13, 2024.

What is the P/E ratio for Prelude Therapeutics stock?

The price to earnings (P/E) ratio for Prelude Therapeutics (PRLD) stock is 0 as of April 13, 2024.

Does Prelude Therapeutics stock pay dividends?

No, Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Prelude Therapeutics dividend payment date?

Prelude Therapeutics (PRLD) stock does not pay dividends to its shareholders.

What is the beta indicator for Prelude Therapeutics?

Prelude Therapeutics (PRLD) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Prelude Therapeutics stock price target?

The target price for Prelude Therapeutics (PRLD) stock is $5.8, which is 3.2% above the current price of $5.62. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Prelude Therapeutics stock

Buy or sell Prelude Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing